Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa.
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EPIDAURE
- Sponsors AstraZeneca
- 11 Oct 2016 Results of EGFR exon 19 Del and L858R mutation subtypes, presented at the 41st European Society for Medical Oncology Congress.
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 21 Aug 2013 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.